Tratamento profilático da enxaqueca: estudo prospectivo aberto com a flunarizina em 100 pacientes

Sanvito, Wilson Luiz; Oliveira, Berenice Cataldo G.

doi:10.1590/S0004-282X1993000100005

Resumos

A eficácia da flunarizina, rua dose de 10 mg/dia, no tratamento profilático da enxaqueca foi avaliada em 100 pacientes durante 120 dias, em um estudo aberto. Noventa e três pacientes completaram o período da terapia referido e em 7 pacientes fomos obrigados a suspender a droga pela presença de importantes efeitos colaterais. Os principais efeitos adversos observados foram ganho de peso, sonolência diurna excessiva, cansaço e depressão do humor. Oitenta e um enxaquecosos se beneficiaram do tratamento, pela abolição das crises ou redução significativa de sua incidência e/ou intensidade. Os resultados permitem concluir que a flunarizina é droga eficaz no tratamento profilático da enxaqueca.

enxaqueca; bloqueadores dos canais de cálcio; flunarizina

The prophylactic value of a daily dose of 10 mg flunarizine, a calcium antagonist, was analysed in 100 migraineurs during 4-month in an open study. Ninety-three patients completed the full 16-week course of therapy, and seven patients presented important adverse reactions requiring discontinuation of the drug. However, the seven patients who dropped out during flunarizine treatment were not considered in the analysis. Side-effects included weight gain, sleepiness, humor depression, paresthesias and dry mouth. Eighty-one patients experienced abolition or significant reduction in headache incidence and/ or severity. We conclude that flunarizine may be an effective drug in migraine prophylaxis.

migraine; calcium channel blockers; flunarizine

Tratamento profilático da enxaqueca: estudo prospectivo aberto com a flunarizina em 100 pacientes

Prophylactic treatment of migraine with flunarizine: a prospective open study in one hundred patients

Wilson Luiz Sanvito^I; Berenice Cataldo G. Oliveira^II

^IProfessor Pleno. Trabalho da Disciplina de Clínica Neurológica da Faculdade de Ciências Médicas da Santa Casa de São Paulo

^IIProfessora Instrutora. Trabalho da Disciplina de Clínica Neurológica da Faculdade de Ciências Médicas da Santa Casa de São Paulo

RESUMO

A eficácia da flunarizina, rua dose de 10 mg/dia, no tratamento profilático da enxaqueca foi avaliada em 100 pacientes durante 120 dias, em um estudo aberto. Noventa e três pacientes completaram o período da terapia referido e em 7 pacientes fomos obrigados a suspender a droga pela presença de importantes efeitos colaterais. Os principais efeitos adversos observados foram ganho de peso, sonolência diurna excessiva, cansaço e depressão do humor. Oitenta e um enxaquecosos se beneficiaram do tratamento, pela abolição das crises ou redução significativa de sua incidência e/ou intensidade. Os resultados permitem concluir que a flunarizina é droga eficaz no tratamento profilático da enxaqueca.

Palavras chave: enxaqueca, bloqueadores dos canais de cálcio, flunarizina.

SUMMARY

The prophylactic value of a daily dose of 10 mg flunarizine, a calcium antagonist, was analysed in 100 migraineurs during 4-month in an open study. Ninety-three patients completed the full 16-week course of therapy, and seven patients presented important adverse reactions requiring discontinuation of the drug. However, the seven patients who dropped out during flunarizine treatment were not considered in the analysis. Side-effects included weight gain, sleepiness, humor depression, paresthesias and dry mouth. Eighty-one patients experienced abolition or significant reduction in headache incidence and/ or severity. We conclude that flunarizine may be an effective drug in migraine prophylaxis.

Key words: migraine, calcium channel blockers, flunarizine.

Full text available only in PDF format.

Texto completo disponível apenas em PDF.

Aceite: 04-julho-1992.

Dr. Wilson Luiz Sanvito Disciplina de Neurologia, Faculdade de Ciências Médicas da Santa Casa Rua Cesário Motta Jr. 112 01221-020 São Paulo SP Brasil

1. Albani F, Baldrati A, Cortelli P, Riva R, Baruzzi A. Flunarizine plasma concentrations and effects in migraine patients. Headache 1990, 30:369-370.
2. Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 1983, 23:70-74.
3. Amery WK. Calcium-entry blockers in migraine: rationale and clinical results. In Ferrari MD, Lataste X (eds): Migraine and other headaches. Carnforth UK: Parthenon, 1989, 217-226.
4. Bussone G, Baldini S, D'Andrea G, Cananzi A, Frediani F, Caresia L, Boiardi A. Nimo-dipine versus flunarizine in common migraine: a controlled pilot trial. Headache 1987, 27:76-79.
5. Diamond S, Schenbaum H. Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. Headache 1983, 23:39-42.
6. Frenken CWGM, Nuijten STM. Flunarizine, a new preventive approach to migraine. Clin Neurol Neurosurg 1984, 86:17-20.
7. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984, 27:6-44.
8. Lauritzen M. Spreading depression: pathophysiology and relation to depression. In Ferrari MD, Lataste X (eds): Migraine and other headaches. Carnforth UK: Parthenon, 1989, p 95-105.
9. Deão AAP. Spreading depression of activity in the cerebral cortex. J Physiol 1944, 7: 359-390.
10. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine. Headache 1981, 21:235-239.
11. Peroutka SJ, Banghardt BS, Allen GS. Relative potency and selectivity of calcium antagonists used in the treatment of migraine. Headache 1984, 24:55-58.
12. Solomon GD. The actions and uses of calcium channel blockers in migraine and cluster headache. Headache Quart 1990, 1:152-159.

Datas de Publicação

Publicação nesta coleção
19 Jan 2011
Data do Fascículo
Mar 1993

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

[1] 1. Albani F, Baldrati A, Cortelli P, Riva R, Baruzzi A. Flunarizine plasma concentrations and effects in migraine patients. Headache 1990, 30:369-370.

[2] 2. Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 1983, 23:70-74.

[3] 3. Amery WK. Calcium-entry blockers in migraine: rationale and clinical results. In Ferrari MD, Lataste X (eds): Migraine and other headaches. Carnforth UK: Parthenon, 1989, 217-226.

[4] 4. Bussone G, Baldini S, D'Andrea G, Cananzi A, Frediani F, Caresia L, Boiardi A. Nimo-dipine versus flunarizine in common migraine: a controlled pilot trial. Headache 1987, 27:76-79.

[5] 5. Diamond S, Schenbaum H. Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. Headache 1983, 23:39-42.

[6] 6. Frenken CWGM, Nuijten STM. Flunarizine, a new preventive approach to migraine. Clin Neurol Neurosurg 1984, 86:17-20.

[7] 7. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984, 27:6-44.

[8] 8. Lauritzen M. Spreading depression: pathophysiology and relation to depression. In Ferrari MD, Lataste X (eds): Migraine and other headaches. Carnforth UK: Parthenon, 1989, p 95-105.

[9] 9. Deão AAP. Spreading depression of activity in the cerebral cortex. J Physiol 1944, 7: 359-390.

[10] 10. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine. Headache 1981, 21:235-239.

[11] 11. Peroutka SJ, Banghardt BS, Allen GS. Relative potency and selectivity of calcium antagonists used in the treatment of migraine. Headache 1984, 24:55-58.

[12] 12. Solomon GD. The actions and uses of calcium channel blockers in migraine and cluster headache. Headache Quart 1990, 1:152-159.